Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged life sciences · clear
Written by : Zachary B. Messick & Brenden S. Gingrich, Ph.D. As retailers or distributors that are not manufacturers of a product, companies may believe they cannot infringe a patent claiming how the product is made. After all, the retailers or…
Written by : Sophia Petrichenko & Jason J. Jardine As predictions of an economic recession in the United States loom, 2023 has started with extensive layoffs throughout the tech industry. Though not to an equal degree, the biotechnology, pharmaceutical,…
Most of the community involved in life science litigation and pharmaceutical companies, thought they saw the end of the long-fought battle between Amgen and Sanofi in 2021 with the CAFC decision . As a result, at the time, it was said that the attorney…
In my first post on the Subcommittee Hearings held last week , I noted the absence of many witnesses from the life science industry, as opposed to groups such as IPO, AIPLA, BIO, ACLU and PhMA. The third and final panel , held yesterday, remedied this…
Although this list will reach most the readers of Patents4Life after 2019 begins, 2018 deserves some attention even if it has the feel of “those we lost in 2018” lists. Although most of my colleague-commentators have published their lists by…
